Health Insurance Law Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Health Insurance Law Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Centre Hospitalier de l'Universite de Henri Mondor, Creteil, France
Breast cancer treated by 24-h continuous intravenous infusion of Yondelis
August 13th, 2006
Response and tumor control in breast cancer could be achieved with Yondelis (trabectedin, ET-743) as a 24-h continuous intravenous infusion. "Yondelis is a novel marine-derived anticancer compound found in the ascidian Ecteinascidia turbinate. It is currently under phase II/III development in breast cancer, hormone refractory prostate cancer, sarcomas and ovarian cancer. Activity in breast cancer experimental models has been reported, and preliminary evidence of activity in this setting during the phase 1 programme has also been observed," scientists in France reported. "The present study assessed the activity and feasibility of trabectedin in...
Source: Health Insurance Law Weekly (2006-08-13)
|
